CompletedPhase 3NCT00803205
Study of Ataluren (PTC124™) in Cystic Fibrosis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PTC Therapeutics
- Principal Investigator
- Temitayo Ajayi, MDPTC Therapeutics
- Intervention
- Ataluren(drug)
- Enrollment
- 238 target
- Eligibility
- 6 years · All sexes
- Timeline
- 2009 – 2011
Study locations (30)
- University of Alabama-Birmingham, Birmingham, Alabama, United States
- Miller Children's Hospital Long Beach, Long Beach, California, United States
- Lucile Packard Children's Hospital, Palo Alto, California, United States
- Stanford, Palo Alto, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- The Children's Hospital, Aurora, Colorado, United States
- University of Miami, Miami, Florida, United States
- Miami Children's Hospital, Miami, Florida, United States
- Emory University Cystic Fibrosis Center, Atlanta, Georgia, United States
- Children's Memorial Hospital, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins Children's Center, Baltimore, Maryland, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- Washington University, St Louis, Missouri, United States
- Beth Israel Medical Center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Cystic Fibrosis Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00803205 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS